VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Child Neurology Society Annual Meeting
PARAMUS, N.J., Sept. 22, 2021 /PRNewswire/ -- NS Pharma, Inc., (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the Child Neurology Society 50th Annual Meeting being held in Boston, Massachusetts from Sept 29 – Oct 2.
The poster presentation will be given by Vamshi Rao, MD, from the Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, and will be available for viewing on September 30th and October 1st. For more information, please visit the Child Neurology Society Annual Meeting website to view the program:
About VILTEPSO® (viltolarsen) injection
Important Safety Information
Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
About NS Pharma, Inc.
View original content:https://www.prnewswire.com/news-releases/viltepso-viltolarsen-injection-interim-long-term-clinical-trial-data-scheduled-for-presentation-at-the-child-neurology-society-annual-meeting-301381935.html
SOURCE NS Pharma